Edition:
India

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

0.22USD
15 Jul 2020
Change (% chg)

$-0.07 (-23.88%)
Prev Close
$0.29
Open
$0.26
Day's High
$0.28
Day's Low
$0.22
Volume
1,905,782
Avg. Vol
309,028
52-wk High
$7.09
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Endologix Enters Agreement With Deerfield Partners To Take Co Private
Monday, 6 Jul 2020 

July 5 (Reuters) - Endologix Inc ::ENDOLOGIX ENTERS INTO AN AGREEMENT WITH DEERFIELD PARTNERS TO TAKE COMPANY PRIVATE.COMMENCES VOLUNTARY CHAPTER 11 PROCESS WITH ACCESS TO $30.8 MILLION IN DIP FINANCING.FILES CONSENSUAL PLAN OF REORGANIZATION THAT WOULD REDUCE $180 MILLION IN DEBT AND PROVIDE $30 MILLION IN ADDITIONAL EXIT FINANCING.CONFIRMS LAUNCH OF ALTO THIS SUMMER, STEADY PRODUCTION, CONTINUED CLINICAL STUDIES, AND ACCELERATED PIPELINE.EXPECTS TO EMERGE WELL CAPITALIZED BY END OF Q3 OF 2020.UNDER TERMS OF PLAN FILED, ENDOLOGIX WILL BECOME A PRIVATE COMPANY.HAS INITIATED A VOLUNTARY CHAPTER 11 CASE AND SIMULTANEOUSLY FILED A CONSENSUAL PLAN OF REORGANIZATION SUPPORTED BY DEERFIELD PARTNERS.COMPANY EXPECTS TO GAIN ACCESS TO $110.8 MILLION OF NEW FINANCING THROUGH THIS PROCESS, INCLUDING $30.8 MILLION IN DIP FINANCING.  Full Article

Endologix Reports Q2 Loss Per Share $1.50
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.SEES Q3 2019 REVENUE $35 MILLION TO $37 MILLION.Q2 LOSS PER SHARE $1.50.Q2 REVENUE $36.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $36 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.83 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q3 REVENUE VIEW $34.5 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $142.2 MILLION -- REFINITIV IBES DATA.  Full Article

First Light Asset Management Reports 13.45 Pct Passive Stake In Endologix Inc As Of April 3
Thursday, 11 Apr 2019 

April 10 (Reuters) - Endologix Inc ::FIRST LIGHT ASSET MANAGEMENT LLC REPORTS 13.45 PERCENT PASSIVE STAKE IN ENDOLOGIX INC AS OF APRIL 3 - SEC FILING.  Full Article

Endologix Sees Q1 2019 Revenue About $35 Million
Tuesday, 26 Feb 2019 

Feb 25 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.26.SEES Q1 2019 REVENUE ABOUT $35 MILLION.Q4 REVENUE $34.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $32 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.REAFFIRMS ITS PREVIOUSLY ISSUED ANNUAL GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $-0.52, REVENUE VIEW $141.6 MILLION -- REFINITIV IBES DATA.Q1 REVENUE VIEW $32.7 MILLION -- REFINITIV IBES DATA.  Full Article

Endologix Sees Q1 Revenue About $35 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 PRELIMINARY FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL GUIDANCE.SEES Q1 2019 REVENUE ABOUT $35 MILLION.SEES FY 2018 REVENUE $155.8 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.SEES Q4 2018 REVENUE ABOUT $34 MILLION.TOTAL CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AS OF DECEMBER 31, 2018 ARE EXPECTED TO BE APPROXIMATELY $24 MILLION.ANTICIPATES REVENUE FOR Q1 ENDING MARCH 31, 2019 OF APPROXIMATELY $35 MILLION.CONTINUES TO EXPECT 2019 OPERATING EXPENSES IN RANGE OF $130 MILLION TO $140 MILLION.ENDOLOGIX - 2019 FINANCIAL GUIDANCE CONTEMPLATES ANTICIPATED IMPACT OF VOLUNTARY RECALL OF NELLIX SYSTEM, ISSUANCE OF JAN 4, 2019 FIELD SAFETY NOTICE.CONTINUES TO EXPECT 2019 REVENUE OF AT LEAST $140 MILLION.Q4 REVENUE VIEW $31.1 MILLION -- REFINITIV IBES DATA.Q1 REVENUE VIEW $31.9 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $140.8 MILLION -- REFINITIV IBES DATA.  Full Article

Endologix Reports Q3 Revenue $34.8 Million
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SEES FY 2018 GAAP LOSS PER SHARE $0.87 TO $0.91.Q3 LOSS PER SHARE $0.12.Q3 REVENUE $34.8 MILLION VERSUS I/B/E/S VIEW $34.5 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.CONTINUES TO ANTICIPATE 2018 REVENUE IN RANGE OF $150 MILLION TO $155 MILLION.2019 OPERATING EXPENSES ANTICIPATED TO BE IN RANGE OF $130 MILLION TO $140 MILLION.FY2019 REVENUE VIEW $142.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $151.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $-0.79 -- THOMSON REUTERS I/B/E/S.  Full Article

Endologix Announces Public Offering Of Common Stock
Thursday, 25 Oct 2018 

Oct 24 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.ENDOLOGIX INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $20.0 MILLION OF ITS SHARES OF COMMON STOCK.ENDOLOGIX - INTENDS TO USE NET PROCEEDS FROM OFFERING TO REDEEM ALL $18.3 MILLION 2.25% CONVERTIBLE SENIOR NOTES DUE 2018.  Full Article

FDA Classifies Previous Endologix Afx Safety Notice As Class I Recall
Saturday, 6 Oct 2018 

Oct 5 (Reuters) - Endologix Inc ::FDA CLASSIFIES PREVIOUS ENDOLOGIX AFX SAFETY NOTICE AS CLASS I RECALL.ENDOLOGIX- RECEIVED NOTICE THAT FDA CLASSIFIED VOLUNTARY RECALL ACTION THAT CO TOOK IN JULY OF THIS YEAR AS A CLASS I RECALL.ENDOLOGIX INC - JULY RECALL INVOLVED CO'S ISSUANCE OF A SAFETY NOTICE TO HEALTHCARE PROFESSIONALS USING AFX ENDOVASCULAR AAA SYSTEM.ENDOLOGIX - NO PRODUCT WAS REMOVED FROM FIELD AS PART OF JULY RECALL.  Full Article

Endologix Announces Q3 Revenue Results, Raises Low-End Of FY Revenue Guidance
Wednesday, 3 Oct 2018 

Oct 2 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES THIRD QUARTER PRELIMINARY REVENUE RESULTS AND RAISES LOW END OF 2018 REVENUE GUIDANCE RANGE.SEES Q3 2018 REVENUE $34.3 MILLION TO $34.7 MILLION.NOW ANTICIPATES 2018 REVENUE TO BE IN RANGE OF $150 MILLION TO $155 MILLION.  Full Article

BRIEF-Endologix Says On July 7, Notified That Nasdaq Has Determined That Co's Common Stock Will Be Delisted

* ENDOLOGIX INC - ON JULY 7, GOT LETTER FROM NASDAQ NOTIFYING IT NASDAQ HAS DETERMINED THAT CO'S COMMON STOCK WILL BE DELISTED FROM NASDAQ